The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 39-48

  Yu, Sheng Qiang ^a,b   Lai, Kuo Pao ^b   Xia, Shu Jie ^a   Chang, Hong Chiang ^c   Chang, Chawnshang ^b   Yeh, Shuyuan ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DIHYDROXYTESTOSTERONE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TESTOSTERONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL ISOLATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN CWR22RV1; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL STRAIN PC3; CELL STRAIN PC346C; CELL STRAIN WPMY 1; CELL SURVIVAL; CELL TRANSFORMATION; COCULTURE; DOWN REGULATION; EXPERIMENTAL MOUSE; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; SUPPRESSOR CELL; UPREGULATION; ANIMAL; DISEASE MODEL; EPITHELIUM CELL; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 69449084106     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.44     Document Type: Review

References (87)

1. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41: 834-45.
2. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
3. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
5. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-6.
6. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: Mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-19.
7. Ricke WA, Wang Y, Kurita T, Hayward SW, Cunha GR. Hormonal and stromal regulation of normal and neoplastic prostatic growth. Prog Mol Subcell Biol 2005; 40: 183-216.
8. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-05.
9. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205-25.
10. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, et al. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115-32.
11. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-40.
12. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005; 5: 8.
13. Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2007; 2: e1006.
14. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005; 4: 505-15.
15. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96: 251-8.
16. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000; 7: 997-1007.
17. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002; 9: 117-25.
18. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-73.
19. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, et al. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002; 50: 222-35.
20. Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Int J Urol 2007; 14: 233-9.
21. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 2006; 13: 151-67.
22. Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, et al. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 1995; 55: 67-76.
23. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12: 941-53.
24. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, et al. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 2000; 73: 237-49.
25. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005; 65: 2082-4.
26. Joly-Pharaboz MO, Kalach JJ, Pharaboz J, Chantepie J, Nicolas B, et al. Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment. J Steroid Biochem Mol Biol 2008; 111: 50-9.
27. Soto AM, Lin TM, Sakabe K, Olea N, Damassa DA, et al. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Oncol Res 1995; 7: 545-58.
28. Takahashi H, Furusato M, Allsbrook Jr WC, Nishii H, Wakui S, et al Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55: 1621-4.
29. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
30. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-65.
31. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 277-85.
32. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
33. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, et al. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006; 66: 1329-38.
34. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, et al. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53: 1304-11.
35. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, et al. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9: 181-8.
36. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000; 141: 1699-704.
37. Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH, et al. Prostate androgen-regulated gene: A novel potential target for androgen-independent prostate cancer therapy. Asian J Androl 2006; 8: 455-62.
38. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-7.
39. Wilson SS, Crawford ED. Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 2006; 12: 799-805.
40. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563-70.
41. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82.
42. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-81.
43. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001; 47: 66-75.
44. Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M, et al. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 2003; 14: 101-12.
45. Nagakawa O, Akashi T, Hayakawa Y, Junicho A, Koizumi K, et al. Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep 2004; 12: 837-41.
46. Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006; 16: 831-6.
47. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35: 403-9.
48. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, et al. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996; 56: 3042-6.
49. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994; 54: 6049-52.
50. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-14.
51. Yeh S, Hu YC, Wang PH, Xie C, Xu Q, et al. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 2003; 198: 1899-908.
52. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996; 149: 1055-62.
53. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000; 43: 263-71.
54. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, et al. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer 2005; 117: 221-9.
55. Cunha GR. Epithelial-stromal interactions in development of the urogenital tract. Int Rev Cytol 1976; 47: 137-94.
56. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004; 67: 417-34.
57. Cunha GR, Donjacour A. Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 1987; 239: 251-72.
58. Cunha GR, Donjacour AA, Sugimura Y. Stromal-epithelial interactions and heterogeneity of proliferative activity within the prostate. Biochem Cell Biol 1986; 64: 608-14.
59. Hayward SW, Baskin LS, Haughney PC, Cunha AR, Foster BA, et al. Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) 1996; 155: 81-93.
60. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, et al. Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 1998; 63: 131-40.
61. Ganjam VK, Amann RP. Steroids in fluids and sperm entering and leaving the bovine epididymis, epididymal tissue, and accessory sex gland secretions. Endocrinology 1976; 99: 1618-30.
62. Robert M, Gagnon C. Sperm motility inhibitor from human seminal plasma: presence of a precursor molecule in seminal vesicle fluid and its molecular processing after ejaculation. Int J Androl 1994; 17: 232-40.
63. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 2972-82.
64. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, et al. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992; 13: 465-75.
65. Cunha GR, Chung LW. Stromal-epithelial interactions - I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 1981; 14: 1317-24.
66. Cunha GR, Lung B. The importance of stroma in morphogenesis and functional activity of urogenital epithelium. In Vitro 1979; 15: 50-71.
67. Chung LW, Cunha GR. Stromal - epithelial interactions - II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 1983; 4: 503-11.
68. Cunha GR, Foster B, Thomson A, Sugimura Y, Tanji N, et al. Growth factors as mediators of androgen action during the development of the male urogenital tract. World J Urol 1995; 13: 264-76.
69. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
70. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, et al. A human prostatic stromal myofibroblast cell line WPMY-1: A model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 1999; 20: 1185-92.
71. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006; 118: 2123-31.
72. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105: 12188-93.
73. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005; 85: 1392-404.
74. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, et al. The current state of preclinical prostate cancer animal models. Prostate 2008; 68: 629-39.
75. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64: 2270-305.
76. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-30.
77. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-91.
78. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996; 24: 502-4.
79. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007; 104: 12679-84.
80. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001; 20: 173-93.
81. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-8.
82. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
83. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003; 63: 3886-90.
84. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 2007; 67: 9089-96.
85. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006; 9: 367-78.
86. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3: 402-8.
87. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002; 99: 2884-9.